{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:36:36Z","timestamp":1762418196995,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.remn.2020.09.002","type":"journal-article","created":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T16:04:49Z","timestamp":1606061089000},"page":"82-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Eficacia y seguridad de la radioembolizaci\u00f3n con 90Y en el tratamiento de met\u00e1stasis hep\u00e1ticas de tumores neuroendocrinos. Seguimiento a largo plazo y repercusi\u00f3n en la supervivencia"],"prefix":"10.1016","volume":"40","author":[{"given":"M.","family":"Tudela-Lerma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Orcajo-Rinc\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Ram\u00f3n-Botella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"\u00c1lvarez-Luque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Gonz\u00e1lez-Leyte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rotger-Regi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Velasco-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Col\u00f3n-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.remn.2020.09.002_bib0180","doi-asserted-by":"crossref","first-page":"724","DOI":"10.6004\/jnccn.2012.0075","article-title":"Neuroendocrine tumors","volume":"10","author":"Kulke","year":"2012","journal-title":"J Natl Compr Canc Netw."},{"key":"10.1016\/j.remn.2020.09.002_bib0185","doi-asserted-by":"crossref","first-page":"973946","DOI":"10.1155\/2012\/973946","article-title":"Treatment of neuroendocrine tumor liver metastases","volume":"2012","author":"Lewis","year":"2012","journal-title":"Int J Hepatol."},{"key":"10.1016\/j.remn.2020.09.002_bib0190","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.21389","article-title":"Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival","volume":"104","author":"Gupta","year":"2005","journal-title":"Cancer."},{"key":"10.1016\/j.remn.2020.09.002_bib0195","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1002\/hep.26947","article-title":"Left-liver hypertrophy after therapeutic right-liver radioembolization is substantial but less than after portal vein embolization","volume":"59","author":"Garlipp","year":"2014","journal-title":"Hepatology."},{"key":"10.1016\/j.remn.2020.09.002_bib0200","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jvir.2018.03.018","article-title":"Radioembolization for Hepatocellular Carcinoma: A Nationwide 10-Year Experience","volume":"29","author":"Tohme","year":"2018","journal-title":"J Vasc Interv Radiol."},{"key":"10.1016\/j.remn.2020.09.002_bib0205","first-page":"370","article-title":"Radioembolization in liver tumours","volume":"38","author":"Carrion-Martin","year":"2019","journal-title":"Rev Esp Med Nucl Imagen Mol."},{"key":"10.1016\/j.remn.2020.09.002_bib0210","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","article-title":"ESMO consensus guidelines for the management of patients with metastatic colorectal cancer","volume":"27","author":"Van Cutsem","year":"2016","journal-title":"Ann Oncol."},{"key":"10.1016\/j.remn.2020.09.002_bib0215","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s12094-019-02182-z","article-title":"Multidisciplinary management of liver metastases in patients with colorectal cancer: a consensus of SEOM, AEC, SEOR, SERVEI, and SEMNIM","volume":"22","author":"Vera","year":"2020","journal-title":"Clin Transl Oncol."},{"key":"10.1016\/j.remn.2020.09.002_bib0220","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1200\/JCO.2015.66.1181","article-title":"SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer","volume":"34","author":"Van Hazel","year":"2016","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remn.2020.09.002_bib0225","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/hpb.12326","article-title":"Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference","volume":"17","author":"Kennedy","year":"2015","journal-title":"HPB (Oxford)."},{"key":"10.1016\/j.remn.2020.09.002_bib0230","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s00259-011-1812-2","article-title":"EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds","volume":"38","author":"Giammarile","year":"2011","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"10.1016\/j.remn.2020.09.002_bib0235","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis."},{"key":"10.1016\/j.remn.2020.09.002_bib0240","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00270-018-2148-0","article-title":"Radioembolization with (90)Y Resin Microspheres of Neuroendocrine Liver Metastases: International Multicenter Study on Efficacy and Toxicity","volume":"42","author":"Braat","year":"2019","journal-title":"Cardiovasc Intervent Radiol."},{"key":"10.1016\/j.remn.2020.09.002_bib0245","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3348\/kjr.2018.19.2.209","article-title":"Imaging Evaluation Following (90)Y Radioembolization of Liver Tumors: What Radiologists Should Know","volume":"19","author":"Joo","year":"2018","journal-title":"Korean J Radiol."},{"key":"10.1016\/j.remn.2020.09.002_bib0250","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/cncr.23685","article-title":"Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases","volume":"113","author":"King","year":"2008","journal-title":"Cancer."},{"key":"10.1016\/j.remn.2020.09.002_bib0255","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/SLA.0b013e3181728a45","article-title":"90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience","volume":"247","author":"Rhee","year":"2008","journal-title":"Ann Surg."},{"key":"10.1016\/j.remn.2020.09.002_bib0260","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000209849","article-title":"Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study","volume":"79","author":"Kalinowski","year":"2009","journal-title":"Digestion."},{"key":"10.1016\/j.remn.2020.09.002_bib0265","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/COC.0b013e31815e4557","article-title":"Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients","volume":"31","author":"Kennedy","year":"2008","journal-title":"Am J Clin Oncol."},{"key":"10.1016\/j.remn.2020.09.002_bib0270","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/bjs.6931","article-title":"Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases","volume":"97","author":"Cao","year":"2010","journal-title":"Br J Surg."},{"key":"10.1016\/j.remn.2020.09.002_bib0275","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.ijrobp.2011.07.041","article-title":"Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes","volume":"83","author":"Memon","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.remn.2020.09.002_bib0280","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00270-011-0248-1","article-title":"Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres","volume":"35","author":"Paprottka","year":"2012","journal-title":"Cardiovasc Intervent Radiol."},{"key":"10.1016\/j.remn.2020.09.002_bib0285","doi-asserted-by":"crossref","first-page":"118","DOI":"10.21037\/jgo.2018.10.05","article-title":"Outcomes and toxicity following Yttrium-90 radioembolization for hepatic metastases from neuroendocrine tumors-a single-institution experience","volume":"10","author":"Zuckerman","year":"2019","journal-title":"J Gastrointest Oncol."},{"key":"10.1016\/j.remn.2020.09.002_bib0290","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1053\/j.semnuclmed.2009.11.001","article-title":"Radioembolization of liver tumors with yttrium-90 microspheres","volume":"40","author":"Ahmadzadehfar","year":"2010","journal-title":"Semin Nucl Med."},{"key":"10.1016\/j.remn.2020.09.002_bib0295","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1097\/SLA.0b013e3181d3d24a","article-title":"Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases","volume":"251","author":"Saxena","year":"2010","journal-title":"Ann Surg."},{"key":"10.1016\/j.remn.2020.09.002_bib0300","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/hep.26191","article-title":"Prognostic factors and prevention of radioembolization-induced liver disease","volume":"57","author":"Gil-Alzugaray","year":"2013","journal-title":"Hepatology."},{"key":"10.1016\/j.remn.2020.09.002_bib0305","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1586\/17474124.2015.959929","article-title":"Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment","volume":"9","author":"Kim","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"10.1016\/j.remn.2020.09.002_bib0310","unstructured":"World Health Organization. WHO handbook for reporting results of cancer treatment. WHO Offset Publication No. 48; Geneva, 1979. Disponible en: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/37200\/WHO_OFFSET_48.pdf."},{"key":"10.1016\/j.remn.2020.09.002_bib0315","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst."},{"key":"10.1016\/j.remn.2020.09.002_bib0320","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"key":"10.1016\/j.remn.2020.09.002_bib0325","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/annonc\/mdh216","article-title":"Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system","volume":"15","author":"Oberg","year":"2004","journal-title":"Ann Oncol."},{"key":"10.1016\/j.remn.2020.09.002_bib0330","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol."},{"key":"10.1016\/j.remn.2020.09.002_bib0335","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11864-011-0148-2","article-title":"New treatment options for patients with advanced neuroendocrine tumors","volume":"12","author":"Chan","year":"2011","journal-title":"Curr Treat Options Oncol."},{"key":"10.1016\/j.remn.2020.09.002_bib0340","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11864-011-0172-2","article-title":"Neuroendocrine pancreatic tumors: guidelines for management and update","volume":"13","author":"Burns","year":"2012","journal-title":"Curr Treat Options Oncol."},{"key":"10.1016\/j.remn.2020.09.002_bib0345","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med."},{"key":"10.1016\/j.remn.2020.09.002_bib0350","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med."}],"container-title":["Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253654X20301748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2253654X20301748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T08:33:27Z","timestamp":1762418007000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2253654X20301748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S2253654X20301748"],"URL":"https:\/\/doi.org\/10.1016\/j.remn.2020.09.002","relation":{},"ISSN":["2253-654X"],"issn-type":[{"type":"print","value":"2253-654X"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eficacia y seguridad de la radioembolizaci\u00f3n con 90Y en el tratamiento de met\u00e1stasis hep\u00e1ticas de tumores neuroendocrinos. Seguimiento a largo plazo y repercusi\u00f3n en la supervivencia","name":"articletitle","label":"Article Title"},{"value":"Revista Espa\u00f1ola de Medicina Nuclear e Imagen Molecular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.remn.2020.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Sociedad Espa\u00f1ola de Medicina Nuclear e Imagen Molecular. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}